Dostinex 0.25mg (Cabergoline)

Adult dose

This medicine is administered orally. Dopamine agonists such as this medicine are better tolerated when taken with food; therefore, for all indications, take this medicine immediately after a meal. 1. Prevention and suppression of lactation 1) Suppression of lactation: Take cabergoline 1mg as a single dose on the first day postpartum 2) Suppression of established lactation: Take cabergoline 0.25mg every 12 hours for 2 days (total 1mg) 2. Treatment of hyperprolactinemia: The recommended initial dose is cabergoline 0.5mg 1∼2 times a week (e.g., 1/2 tablet on Monday and Thursday). Gradually increase the dose by 0.5mg of cabergoline per week, preferably at monthly intervals, until an optimal therapeutic response is achieved. The usual therapeutic dose is cabergoline 1mg per week, administered within a range of 0.5mg∼2mg per week. However, the maximum dose should not exceed cabergoline 4.5mg per week or 3mg per day. Adjust the frequency of administration to once weekly or 2 or more times per week, according to the patient's adherence to treatment. Since tolerability of doses of cabergoline 1mg or more taken once weekly has been evaluated in only a small number of patients, divided doses are recommended when taking cabergoline 1mg or more per week. During dose escalation, evaluate the patient to determine the minimum dose that produces a therapeutic response. Monitor serum prolactin levels monthly. Once an effective therapeutic dose is reached, serum prolactin levels usually return to normal within 2∼4 weeks. Symptoms of hyperprolactinemia may recur after discontinuation of this medicine. In some patients, prolactin levels have been observed to remain low for several months. In follow-up of a group of women who discontinued this medicine, ovulatory cycles continued for more than 6 months after discontinuation in 23 of 29 women.

This medication contains cabergoline and should not be administered to certain patients. In particular, it should not be used in patients with a history of allergy to its components or ergot alkaloids, patients with fibrotic disorders such as pulmonary fibrosis, pericardial fibrosis, or retroperitoneal fibrosis, patients with severely impaired liver function, patients with preeclampsia, patients on antipsychotic medications, patients with a history of postpartum psychiatric disorders, or patients diagnosed with valvular heart disease. Furthermore, caution should be exercised in patients with liver or kidney dysfunction, a history of severe cardiovascular disease or mental disorder, patients at risk of hypotension, pregnant women or women of childbearing potential, patients with genetic issues such as lactose intolerance, and patients with pituitary tumors that have expanded to cause visual disturbances. This medication may cause side effects based on dosage, such as dizziness, headaches, abdominal pain, dyspepsia, hypotension, valvular heart disease, skin rash, depression, sleep disturbances, and so on. Regular echocardiographic examinations to monitor valvular heart condition are important in case of long-term use. During treatment, postural hypotension may occur, so sudden posture changes should be cautious, and caution is also needed when driving or operating machinery. Additionally, psychiatric changes such as impulse control disorders may occur, and immediate consultation with healthcare professionals is recommended if symptoms arise. This medication acts on dopamine receptors, so it may reduce effectiveness when taken with dopamine antagonists, and should also be avoided in combination with certain antibiotics. Women who are pregnant or planning to become pregnant should avoid this medication, and if pregnancy is confirmed during treatment, it should be discontinued immediately. Women who are breastfeeding should also be advised to discontinue breastfeeding as this medication can suppress lactation. Safety in children or adolescents under 19 years of age has not been established, and although no specific risks have been reported in the elderly, caution is warranted. In cases of overdose, symptoms such as vomiting, hypotension, and mental confusion may occur, requiring immediate medical assistance. This medication should be kept out of the reach of children, and transferring to another container is discouraged as it can affect the quality of the medication.

• Orthostatic hypotension
• vascular spasm of fingers
• syncope
• leg cramps
• muscle weakness
• hair loss
• pruritus
• rash
• allergic skin reactions
• decreased hemoglobin levels

This medication is sensitive to light and should be stored in a container that protects it from light. Additionally, it is important to store the medication at room temperature, i.e., below 25 degrees Celsius. This way, the effectiveness of the medication can be maintained for a longer period.

Appearance

Pink oval tablet

Package unit

PTP - 30 tablets/PTP [10 tablets/PTP X 3], PTP - 10 tablets/PTP [10 tablets/PTP (for export)]